RS50605B - Satraplatina za tretiranje rezistentnih i otpornih tumora - Google Patents

Satraplatina za tretiranje rezistentnih i otpornih tumora

Info

Publication number
RS50605B
RS50605B RSP-2008/0408A RSP20080408A RS50605B RS 50605 B RS50605 B RS 50605B RS P20080408 A RSP20080408 A RS P20080408A RS 50605 B RS50605 B RS 50605B
Authority
RS
Serbia
Prior art keywords
cancer
resistance
tumor
resistant
cell
Prior art date
Application number
RSP-2008/0408A
Other languages
English (en)
Serbian (sr)
Inventor
Maureen Caligiuri
Katja Wosikowski-Buters
Anna Maria Casazza
Original Assignee
Gpc Biotech Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gpc Biotech Ag. filed Critical Gpc Biotech Ag.
Publication of RS50605B publication Critical patent/RS50605B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
RSP-2008/0408A 2004-02-18 2005-02-18 Satraplatina za tretiranje rezistentnih i otpornih tumora RS50605B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54609704P 2004-02-18 2004-02-18
PCT/EP2005/001733 WO2005077385A2 (en) 2004-02-18 2005-02-18 Methods for treating resistant or refractory tumors

Publications (1)

Publication Number Publication Date
RS50605B true RS50605B (sr) 2010-05-07

Family

ID=34860531

Family Applications (1)

Application Number Title Priority Date Filing Date
RSP-2008/0408A RS50605B (sr) 2004-02-18 2005-02-18 Satraplatina za tretiranje rezistentnih i otpornih tumora

Country Status (19)

Country Link
US (1) US20080058411A1 (https=)
EP (2) EP1967189A1 (https=)
JP (1) JP2007523123A (https=)
CN (1) CN1933829A (https=)
AT (1) ATE397924T1 (https=)
AU (1) AU2005211937B2 (https=)
CA (1) CA2555811A1 (https=)
CY (1) CY1108780T1 (https=)
DE (1) DE602005007471D1 (https=)
DK (1) DK1720540T3 (https=)
ES (1) ES2308451T3 (https=)
HR (1) HRP20080422T3 (https=)
IL (1) IL177555A0 (https=)
PL (1) PL1720540T3 (https=)
PT (1) PT1720540E (https=)
RS (1) RS50605B (https=)
SI (1) SI1720540T1 (https=)
WO (1) WO2005077385A2 (https=)
ZA (1) ZA200607780B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ2004964A3 (cs) * 2004-09-14 2006-03-15 Pliva-Lachema A. S. Perorální farmaceutická kompozice pro cílený transport komplexu platiny do kolorektální oblasti, zpusob její prípravy a tato kompozice pro pouzití jako lécivo
EP1905437A1 (en) * 2006-09-24 2008-04-02 GPC Biotech AG Treatment of pain using satraplatin
EP1905439A1 (en) * 2006-09-24 2008-04-02 GPC Biotech AG Second line treatment of metastatic hormone refractory prostate cancer using satraplatin
FR2906533B1 (fr) 2006-09-28 2013-02-22 Pf Medicament Procede de generation d'anticorps actifs contre un antigene de resistance,anticorps obtenus par ledit procede et leurs utilisations
JP2010518088A (ja) * 2007-02-09 2010-05-27 ポニアード ファーマシューティカルズ， インコーポレイテッド カプセル化されたピコプラチン
RU2455991C1 (ru) * 2011-07-05 2012-07-20 Учреждение Российской академии медицинских наук Научно-исследовательский институт фармакологии Сибирского отделения РАМН Средство, препятствующее развитию нарушений в легочной ткани при цитостатическом воздействии

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4329299A (en) 1979-08-23 1982-05-11 Johnson, Matthey & Co., Limited Composition of matter containing platinum
GB8328218D0 (en) 1983-10-21 1983-11-23 Johnson Matthey Plc Oral compositions
GB8416048D0 (en) 1984-06-22 1984-07-25 Johnson Matthey Plc Anti-tumour compounds of platinum
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4710384A (en) 1986-07-28 1987-12-01 Avner Rotman Sustained release tablets made from microcapsules
US5072011A (en) 1988-02-02 1991-12-10 Johnson Matthey, Inc. Pt(IV) complexes
US5244919A (en) 1988-02-02 1993-09-14 Johnson Matthey, Inc. Pt(IV) complexes as anti-tumor agents
US4942184A (en) 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol
GB8806044D0 (en) 1988-03-14 1988-04-13 Johnson Matthey Plc Platinum coordination compounds
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5440056A (en) 1992-04-17 1995-08-08 Abbott Laboratories 9-deoxotaxane compounds
US6025473A (en) * 1992-10-27 2000-02-15 Queen's University At Kingston Multidrug resistance proteins
AP9300587A0 (en) 1992-11-12 1995-05-05 Glaxo Inc Water soluble camptothecin derivatives.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5475322A (en) 1993-10-12 1995-12-12 Wang Laboratories, Inc. Clock frequency multiplying and squaring circuit and method
US6210917B1 (en) 1993-12-29 2001-04-03 The Regents Of The University Of California Method for suppressing multiple drug resistance in cancer cells
GB9408218D0 (en) 1994-04-26 1994-06-15 Johnson Matthey Plc Improvements in platinum complexes
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5547982A (en) 1995-02-27 1996-08-20 Johnson Matthey, Inc. Anti-tumor platinum complexes
US20040072889A1 (en) * 1997-04-21 2004-04-15 Pharmacia Corporation Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
US6413953B1 (en) 1999-04-13 2002-07-02 Anormed Inc. Pt(IV) antitumor agent
DK1165576T3 (da) 1999-04-13 2006-03-27 Anormed Inc Fremgangsmåde til fremstilling af amin-platin-komplekser
US7179588B1 (en) 1999-05-20 2007-02-20 Board Of Regents Of The University Of Texas System Assay for the detection of paclitaxel resistant cells in human tumors
US6380405B1 (en) 1999-09-13 2002-04-30 Nobex Corporation Taxane prodrugs
CA2307393A1 (en) * 2000-05-01 2001-11-01 The University Of British Columbia Ginsenoside chemotherapy
US6894049B1 (en) 2000-10-04 2005-05-17 Anormed, Inc. Platinum complexes as antitumor agents
US7351542B2 (en) 2002-05-20 2008-04-01 The Regents Of The University Of California Methods of modulating tubulin deacetylase activity
US6933302B2 (en) 2002-06-03 2005-08-23 California Pacific Medical Center Nitrogen-based homo-camptothecin derivatives
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment

Also Published As

Publication number Publication date
EP1720540A2 (en) 2006-11-15
JP2007523123A (ja) 2007-08-16
CN1933829A (zh) 2007-03-21
WO2005077385A2 (en) 2005-08-25
HK1094313A1 (en) 2007-03-30
AU2005211937B2 (en) 2009-02-26
US20080058411A1 (en) 2008-03-06
PL1720540T3 (pl) 2008-11-28
EP1720540B1 (en) 2008-06-11
ES2308451T3 (es) 2008-12-01
CA2555811A1 (en) 2005-08-25
DE602005007471D1 (de) 2008-07-24
WO2005077385A3 (en) 2005-11-10
EP1967189A1 (en) 2008-09-10
ZA200607780B (en) 2008-04-30
DK1720540T3 (da) 2008-10-06
SI1720540T1 (sl) 2008-12-31
PT1720540E (pt) 2008-09-10
HRP20080422T3 (hr) 2008-09-30
CY1108780T1 (el) 2014-04-09
ATE397924T1 (de) 2008-07-15
IL177555A0 (en) 2006-12-10
AU2005211937A1 (en) 2005-08-25

Similar Documents

Publication Publication Date Title
Rahmanian-Devin et al. [Retracted] Noscapine, an emerging medication for different diseases: a mechanistic review
EP2298292A2 (en) Kinase inhibitors for treating cancers
US20100021420A1 (en) Combinations of pyrazole derivatives for the inhibition of cdks and gsk's
EP1700598B1 (en) Anti-proliferative combination therapy comprising satraplatin or JM118 and docetaxel
ES2403006T3 (es) Antagonistas de la vía Hedgehog para tratar enfermedades
JP2009515857A (ja) 特定の白金系化学療法剤とｅｇｆｒ阻害剤又はピリミジン類似体とを用いた抗増殖併用療法
Kawakami et al. A novel fusicoccin derivative preferentially targets hypoxic tumor cells and inhibits tumor growth in xenografts
CA3097875A1 (en) Abcb5 ligands and substrates
BRPI0708307B1 (pt) Combinação farmacêutica para administração simultânea, separada ou sequencial, e, uso de um peptídeo como inibidor do sítio de fosforilação sobre os substratos de CK2 e um citostático farmaceuticamente aceitável
HK1219879A1 (zh) 用於治疗癌症的包含mps-1激酶抑制剂和有丝分裂抑制剂的组合
RS50605B (sr) Satraplatina za tretiranje rezistentnih i otpornih tumora
Zhang et al. P-glycoprotein-evading anti-tumor activity of a novel tubulin and HSP90 dual inhibitor in a non-small-cell lung cancer model
Chemmalar et al. Busting the breast cancer with AstraZeneca’s Gefitinib
HK1094313B (en) Satraplatin for treating resistant or refractory tumors
Moskaleva et al. Molecular mechanisms of antitumor activity of niclosamide
US20160272652A1 (en) Benzo-thiazolo-imidazole compounds and uses thereof
Aviles et al. PM534, a Novel Colchicine Site Tubulin Inhibitor with Broad-Spectrum and Resistance-Overcoming Antitumor Activity
Dai Unraveling Anticancer Activity And Pharmacokinetics Of Dihydroartemisinin Dimer Oxime
Chatterji et al. Microtubules as Anti-Cancer Drug Targets
Krystof et al. Active p53 contributes to antitumor effects of cyclin-dependent kinase roscovitine in multiple myeloma cells
Biroccio et al. The G-quadruplex ligand RHPS4 interferes with telomere replication leading to ATR-dependent DNA damage response